Wells Fargo analyst Nathan Treybeck lowered the firm’s price target on Procept BioRobotics (PRCT) to $34 from $51 and keeps an Overweight rating on the shares. The firm says the company’s Q4 print and lowered 2026 guidance were disappointing as it works through its strategic shift on customer handpiece inventory levels and commercial org disruption. All eyes are on the investor day to make a case for the second half of the year-heavy guide, Wells adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics downgraded to Underperform from Neutral at BofA
- PROCEPT BioRobotics: Commercial Reset Creates Near-Term Headwinds but Strengthens Long-Term Buy Thesis
- Buy Rating on Aquablation Developer: Short-Term Execution Headwinds Masking Long-Term Medtech Upside
- Closing Bell Movers: Nvidia pares post-earnings gains
- Procept BioRobotics reports Q4 EPS (53c), consensus (32c)